Preclinical Results Presented at the American Society of Hematology Annual Meeting SEATTLE, Dec 08, 2008 (BUSINESS WIRE) -- Calistoga Pharmaceuticals, Inc., the leader in the development of ...
Targeted therapy with imatinib has transformed the treatment of chronic myeloid leukemia (CML). Unlike CML, chronic lymphocytic leukemia (CLL) lacks a common genetic aberration but does demonstrate ...
SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and ...
DUBLIN--(BUSINESS WIRE)--The "Copiktra" report has been added to ResearchAndMarkets.com's offering. Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the ...
INDIANAPOLIS, April 5, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals today announced encouraging preclinical results for its lead product candidate, SF1126, in certain B-cell malignancies. The ...
Myriad of Groups Are Working on the Latest Hot Target and Most Are Optimistic About Its Potential Although the term “signal transduction” was coined back in 1972, cell-signaling switches have only ...
SEATTLE -- Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, ...
Merkel Cell Carcinoma (MCC) is a highly aggressive cancer of the skin. It is characterized by a high recurrence rate and a very poor five-year prognosis. Drugs targeting the programmed cell death ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results